CenterBook Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

CenterBook Partners’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-34,878	Closed	-$3.56M	–	520
2023 Q2	$3.56M	Buy	+34,878	New	+$3.3M	0.44%	66

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

CenterBook Partners's RETA Position: Q3 2023 in Review

CenterBook Partners sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 34,878 shares — an estimated $3.56M sold.

CenterBook Partners first reported a position in RETA in Q2 2023 and held it in 1 quarter. The position peaked at $3.56M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

CenterBook Partners reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
CenterBook Partners sold 34,878 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $3.56M.
CenterBook Partners first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2023 and held it in 1 quarter.
CenterBook Partners's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.56M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on CenterBook Partners's 13F filing for Q3 2023, filed 13 Nov 2023.